Will Neuracle’s brain–computer implant begin real commercial use in China after approval?

China has approved the first invasive brain–computer interface (BCI) for commercial use developed by Neuracle Technology (Shanghai). The authorization was granted by the National Medical Products Administration, allowing the device to be marketed for medical treatment. The implant targets adults with partial paralysis caused by spinal cord injuries. In clinical trials involving 36 patients, the system helped improve the ability to grasp and hold objects by translating brain signals into commands that control a robotic glove. The technology includes implanted brain sensors, neural signal decoding algorithms, surgical tools, and rehabilitation hardware. China has identified neurotechnology as a strategic “industry of the future,” and companies in the country are increasingly competing with international developers such as Neuralink. The uncertainty lies in whether the device will move beyond clinical trials and begin real commercial implantation in hospitals after receiving regulatory approval.